Brief: Seegene Announces Submission To U.S. FDA For Emergency Use Authorization Of Its Allplextm Sars-Cov-2/Flua/Flub/Rsv Assay
01/03/2021 14:33
March 1 (Reuters) - Seegene Inc 096530.KQ :
* SEEGENE ANNOUNCES SUBMISSION TO U.S. FDA FOR EMERGENCY USE
AUTHORIZATION OF ITS ALLPLEXTM SARS-COV-2/FLUA/FLUB/RSV ASSAY
* SEEGENE INC - REAL-TIME TEST DIFFERENTIATES INFLUENZA A &
B, RSV
AND COVID-19
Source text for Eikon: ID:nBw6JwfDza
Further company coverage: 096530.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seegene
See all newsBrief: Seegene To Cancel 174 Billion Won Worth Of Own Shares
Brief: Seegene Q4 Operating Profit 7 Billion Won, Swings To Profit From Year Earlier
Brief: Seegene Establishes French Subsidiary To Expand European Footprint
Brief: Seegene Q2 Operating Profit 3 Billion Won, Swings To Profit From Year Earlier
Brief: Seegene Q1 Operating Profit 14.8 Billion Won, Swings To Profit From Year Earlier